Galmed Pharmaceuticals Ltd. (GLMD)Ramat Gan, Israel |
USD
|
Hot Take ↕ | Oct. 10, 2026, 1:22 p.m. UTC
The immediate outlook is severely clouded by a lack of catalysts and deteriorating technicals. While the stock recently rallied on news regarding a brain-penetrating formulation, the price action over the last two weeks tells a different story, drifting lower from $3.82 to $3.36 before a minor rebound, indicating weak follow-through. The statistical forecasting model offers no guidance due to insufficient data, leaving the short-term path undefined and risky. Fundamentally, the company is in distress with negative earnings, negative free cash flow, and a trailing P/E that implies massive losses. The balance sheet shows significant leverage relative to equity, and the operating cash flow is burning capital. There is no dividend to provide a floor, and the absence of analyst recommendations suggests institutional avoidance. The recent news of terminating a license agreement further erodes confidence in the pipeline's execution. Without a clear turnaround in profitability or a definitive catalyst to drive volume, the risk of further downside outweighs any speculative upside. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 1.013 |
| Market Cap | 4,945,923 |
| Forward P/E | -4.50 |
| Beta | 0.67 |
| Website | https://eocn.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.06701028 |
| Address1 | 16 Abba Hillel Road |
| All Time High | 4.88 |
| All Time Low | 3.12 |
| Ask | 5.05 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 7,941 |
| Average Volume | 30,166 |
| Average Volume10Days | 7,941 |
| Beta | 0.666 |
| Bid | 2.66 |
| Bid Size | 200 |
| Book Value | 12.72 |
| City | Ramat Gan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Currency | USD |
| Current Price | 4.63 |
| Current Ratio | 4.162 |
| Day High | 4.63 |
| Day Low | 3.82 |
| Debt To Equity | 1.013 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -7,486,967 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fax | 972 3 693 8447 |
| Fifty Day Average | 3.6449125 |
| Fifty Two Week High | 4.88 |
| Fifty Two Week Low | 3.12 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 975,788 |
| Forward Eps | -1.03 |
| Forward P E | -4.495146 |
| Free Cashflow | -5,274,625 |
| Full Time Employees | 3 |
| Fullday Change | 0.805 |
| Fullday Change Percent | 0.210458 |
| Fullday Price | 4.63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.03039 |
| Held Percent Institutions | 0.018919999 |
| Implied Shares Outstanding | 1,068,234 |
| Industry | |
| Industry Key | |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. |
| Long Name | Galmed Pharmaceuticals Ltd. |
| Market Cap | 4,945,923 |
| Max Age | 86,400 |
| Message Board Id | finmb_114779940 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -11,343,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,867,007 |
| Open | 3.91 |
| Operating Cashflow | -8,543,000 |
| Operating Margins | 0.0 |
| Phone | 972 3 693 8448 |
| Previous Close | 3.825 |
| Price Hint | 4 |
| Price To Book | 0.3639937 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.106 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 4.63 |
| Regular Market Day Low | 3.82 |
| Regular Market Open | 3.91 |
| Regular Market Previous Close | 3.825 |
| Regular Market Volume | 301,155 |
| Return On Assets | -0.30187 |
| Return On Equity | -0.68206 |
| Sand P52 Week Change | 0.17502642 |
| Sector | |
| Sector Key | |
| Shares Outstanding | 1,068,234 |
| Short Name | Galmed Pharmaceuticals Ltd. |
| Symbol | GLMD |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 11,231,000 |
| Total Cash Per Share | 11.215 |
| Total Debt | 129,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -14.29 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 3.6449125 |
| Underlying Symbol | GLMD |
| Uuid | ade4d27e-0850-308a-ae7b-98b5c772bca9 |
| Volume | 301,155 |
| Website | https://eocn.com |
| Zip | 5,250,608 |